These Mexedia operators have lied and obfuscated so much this past year that it is impossible to see what they have done even using their own statements in the press releases and filings. Conspicuously absent from the Mexedia Rome Italy press release to their shareholders dated December 30th is any mention of Raadr or the Americrew letter of intent. The Americrew deal proposed $750K of the reg A funds packaged as a forgivable loan. I'm thinking that deal was just cover for what they really did. Either that or the $750K and Americrew acquisition went over to Spectral Capital along with the Telvantis U.S. operations. They could have used the proceeds from the reg A plus conversions to pay out the five notes to three individuals totaling $1,050,000 plus interest as performance bonuses.
The company can not hide from what they did. The con to sell 1.3 billion shares of that reg A offering before they filed the Q2 report had two very important parts. The first is that they updated nearly weekly the share structure on the OTC site for months without revealing the ongoing dilution. Post # 48002 shows the near weekly updates since the beginning of the year showing the 25 million shares of the first tranche of the reg A being issued. After that they report zero increases.
The second very important part is the false share buy back narrative. This gave the company a certain air of legitimacy to be able to buy back shares though the business is cash flow negative. This also encourages people to buy the stock, but convincing people hold was key to the price increase. The company then tweets out on the 27th "buyback has started today!". The sales of the reg A began in earnest on that day. Details and links in post# 48921 linked below.